Lv2
170 积分 2024-07-23 加入
Identification and characterization of an antagonistic anti-mouse CD40 antibody
6天前
已关闭
Advances in the treatment of systemic lupus erythematosus
28天前
已完结
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
1个月前
已完结
Tailored treatment strategies and future directions in systemic lupus erythematosus
1个月前
已完结
The emerging role of BLyS/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential
1个月前
已完结
Update on the pathophysiology and treatment of primary Sjögren syndrome
1个月前
已完结
Efficacy and safety of pharmacological treatment for Sjögren’s disease: a network meta-analysis
1个月前
已完结
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study
1个月前
已完结
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
1个月前
已完结
The colorectal cancer drug market
2个月前
已完结
皖公网安备34019202002308
